Korsana Biosciences
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +154.9% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 0.4% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 35.45
- Open
- 35.63
- Day range
- 34.08 - 39.41
- Avg price
- 37.33
- Volume
- 265.24K
- Turnover
- 9.90M
- Turnover ratei
- 0.81%
- Volume ratioi
- 1.01
- Amplitudei
- 15.04%
- 52-week rangei
- 7.19 - 59.36
Valuation
- P/Ei
- -53.66
- P/E (TTM)i
- -53.66
- P/Bi
- 4.37
- EPSi
- -0.70
- Book value / shi
- 8.60
- Net profit
- -31.88M
- Net assets
- 391.56M
Share structure
- Market cap
- 1.71B
- Float capi
- 1.23B
- Shares out
- 45.54M
- Float sharesi
- 32.75M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
36.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-7.42M net over the window
Short interest
- Shares short
- 167.37K
- % of floati
- 0.37%
- Days to coveri
- 1.00
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Korsana Biosciences (KRSA)?
Korsana Biosciences last traded at 37.56. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Korsana Biosciences's market cap?
About 1.71B.
What is the P/E ratio of Korsana Biosciences?
The trailing twelve-month P/E is -53.66. The Valuation tab shows it against the stock's own five-year range.
Does Korsana Biosciences pay a dividend?
Korsana Biosciences does not currently pay a regular dividend.
Is Korsana Biosciences a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 51.20, which implies 36.3% upside from the current price. This is not investment advice.
What is Korsana Biosciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Korsana Biosciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Korsana Biosciences discussion 0 comments